Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
206.590
-0.170
-0.08%
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolio
Allianz Biotechnologie A Eur (0P00000CML)
Add to/Remove from a Portfolio
Add to Watchlist
Allianz Biotechnologie A EUR
206.590
-0.170
-0.08%
- Overview
- Profile
- Historical Data
- Holdings
0P00000CML Overview
On this page you'll find an in-depth profile of Allianz Biotechnologie A Eur. Learn about the key management, total assets, investment strategy and contact information of 0P00000CML among other information.
Investment Strategy
The Fund aims to generate capital growth in the long term by mainly investing in biotechnologyrelated companies within the investment principles. The Fund shall invest in equities, equity equivalent securities and participation certificates, if they are listed on the NASDAQ Biotechnology or if, according to the latest annual report, the issuer’s (or, in the case of instruments representing equities, the corporation’s) majority of sales or profits or expenses can be attributed to the research, development and production of biotechnology goods, processes and services.
Contact Information
Address
L-2633 Senningerberg
Frankfurt am Main, 60323
Germany
Frankfurt am Main, 60323
Germany
Phone
+49 (0) 69 2443-1140
Fax
Frankfurt am Main
Top Executives
| Name | Title | Since | Until |
|---|---|---|---|
| Peter Pirsch | Senior Portfolio Manager | 2019 | Now |
| Biography | Mr. Pirsch is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 20 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an associate director at UBS Investment Bank and an analyst at Wells Fargo. He has a B.A. in economics and international relations from Bucknell University, and an M.B.A. with a certificate in health sector management from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder. | ||
| Christopher Chin | - | 2019 | Now |
| Kimberlee W. Millar | Vice President | 2018 | 2021 |
| Biography | Ms. Millar is a portfolio manager, analyst and director with Allianz Global Investors, which she joined in 2005. As a generalist for the Disciplined Equities group, her primary responsibility is conducting company research; she also helps improve the group’s overall investment processes and contributes toward its portfolio-management efforts. Ms. Millar has 23 years of investment industry experience. She previously worked as an assistant economist at the Investment Company Institute in Washington, D.C., producing mutual-fund-industry research for investment-management firms’ research and marketing departments. Before that, Ms. Millar worked at Heiden Associates Inc., an economic consulting firm in Washington, D.C. She has a B.A. in economics from the University of Calgary, Canada, and an M.A. in economics from Queen’s University, Canada. Ms. Millar is a CFA charterholder and a member of the CFA Institute. | ||
| Hugo Ong | - | 2018 | 2021 |
| Christopher Chin | - | 2018 | 2019 |
| Peter Pirsch | Senior Portfolio Manager | 2018 | 2019 |
| Biography | Mr. Pirsch is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 20 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an associate director at UBS Investment Bank and an analyst at Wells Fargo. He has a B.A. in economics and international relations from Bucknell University, and an M.B.A. with a certificate in health sector management from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder. | ||
| John R. Schroer | Portfolio Manager | 2014 | 2018 |
| Biography | Mr. Schroer, CFA, is a portfolio manager and a director with Allianz Global Investors, which he joined in 2014. He is the sector head of the Health Care team. He was previously the president of Schroer Capital, L.P.; an equity analyst with HealthCor Management, L.P.; a managing member and portfolio manager for ITROS Capital Management, LLC; a global partner, senior vice president, and portfolio manager for INVESCO; and an analyst for Trust Company of the West. Mr. Schroer has a B.S. in history and international relations and an M.B.A. in finance from the University of Wisconsin. | ||
| Paul A. Wagner | Senior Research Analyst | 2012 | 2014 |
| Biography | Mr. Wagner, CFA, is a portfolio manager, a senior research analyst and a director with Allianz Global Investors, which he joined in 2006. He has biotechnology responsibilities for the US Health Care team and has 14 years of investment-industry experience. Mr. Wagner previously worked at PDL BioPharma in corporate and business development, and was a vice president and senior equity-research analyst in the biotechnology sector at Lehman Brothers. He has a B.S. in chemistry from the University of Wisconsin and a Ph.D. in chemistry from the California Institute of Technology. | ||
| Nicole Papassavvas | - | 2008 | 2012 |
| Javier Latorre | - | 2007 | 2012 |
Write your thoughts about Allianz Biotechnologie A Eur
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review